Why do so many people lack access to healthcare?
Millions of people living with diabetes and rare blood disorders cannot get the life-saving medicine they need. In some instances, medicine is too costly, or travelling to see the doctor or to pick up a prescription requires a long journey and a loss of wages.
In extreme situations, there is no doctor to see, healthcare clinic to go to, or medicine on the shelf at the pharmacy.
The stark reality is that only a fraction of patients are being treated today – and we need to close that gap so that people have affordable access to the medicines we manufacture and the care they need.
The barriers are complex and differ from country to country, but we know from experience that change is possible.
Our ambition is to provide access to the medicines we have available, to the greatest number of people living with diabetes, rare blood diseases and rare endocrine disorders, while addressing varying levels of affordability.
In low- and middle-income countries, we put extra focus on the most vulnerable people living with diabetes. In more than two-thirds of the countries where we operate, we have established affordability and access programmes to help patients in need.
These programmes are working to answer tough questions, like:
How do we encourage more patients to enrol in affordability programmes?
How do we design insulins that don’t require cooling and can therefore travel further?
How can we simplify medicine supply chains to drive down price?
We are working on these questions with a strong commitment to making insulin available to all. Read on and learn more about our commitment to affordable treatment and access to diabetes care.
Mithila Hag Farin and her mother. Mithila lives in Bangladesh and has type 1 diabetes
See how partnerships are improving health systems and lives in Tanzania, and worldwide
In some countries, people living with haemophilia may be in a situation where they are not authorised to store their haemophilia medication at home. For example, during the COVID-19 crisis, they have not been able to visit hospitals to seek treatment.
When people living with a rare blood disease face these situations, we work with local health authorities and partner organisations to provide financial support for medicine and treatment home delivery.
To ensure clear and transparent relationships, our initiatives are designed in dialogue with policy makers, for support services related to patient training, delivery and medicine storage.
As a child, Carlos Maube nearly lost his life to haemophilia due to a lack of care in his hometown of Mombasa, Kenya.
Americans using our $25 low-cost insulin programme.
people with diabetes treated with our human insulin at a maximum of USD 3 per 10ml vial.
people using our diabetes care products globally.
people with haemophilia and family members benefitting from educational activities led by the Novo Nordisk Haemophilia Foundation.
The way our medicines are priced and reimbursed varies a lot between countries. We believe new outcomes-based pricing models will contribute to better evaluation of the true value of our medicines. Our commitment is to drive initiatives aimed at finding innovative, outcomes-based pricing models in close collaboration with other key stakeholders.